SYEDA Drug Patent Profile
✉ Email this page to a colleague
When do Syeda patents expire, and when can generic versions of Syeda launch?
Syeda is a drug marketed by Xiromed and is included in one NDA.
The generic ingredient in SYEDA is drospirenone; ethinyl estradiol. There are eleven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Syeda
A generic version of SYEDA was approved as drospirenone; ethinyl estradiol by DR REDDYS LABS SA on September 7th, 2010.
US Patents and Regulatory Information for SYEDA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiromed | SYEDA | drospirenone; ethinyl estradiol | TABLET;ORAL-28 | 090114-001 | Mar 28, 2011 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
